- Home
- IBRX vs FCPT Comparison
IBRX vs FCPT Comparison
Compare IBRX & FCPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- FCPT
- Stock Information
- Founded
- IBRX 2014
- FCPT 2015
- Country
- IBRX United States
- FCPT United States
- Employees
- IBRX N/A
- FCPT N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- FCPT Real Estate Investment Trusts
- Sector
- IBRX Health Care
- FCPT Real Estate
- Exchange
- IBRX Nasdaq
- FCPT Nasdaq
- Market Cap
- IBRX 2.3B
- FCPT 2.5B
- IPO Year
- IBRX N/A
- FCPT N/A
- Fundamental
- Price
- IBRX $2.58
- FCPT $23.86
- Analyst Decision
- IBRX Strong Buy
- FCPT Buy
- Analyst Count
- IBRX 6
- FCPT 5
- Target Price
- IBRX $9.83
- FCPT $28.75
- AVG Volume (30 Days)
- IBRX 9.7M
- FCPT 533.4K
- Earning Date
- IBRX 11-10-2025
- FCPT 10-28-2025
- Dividend Yield
- IBRX N/A
- FCPT 5.95%
- EPS Growth
- IBRX N/A
- FCPT 1.85
- EPS
- IBRX N/A
- FCPT 1.08
- Revenue
- IBRX $56,600,000.00
- FCPT $279,445,000.00
- Revenue This Year
- IBRX $629.94
- FCPT $12.06
- Revenue Next Year
- IBRX $109.91
- FCPT $4.17
- P/E Ratio
- IBRX N/A
- FCPT $22.10
- Revenue Growth
- IBRX 4227.22
- FCPT 6.29
- 52 Week Low
- IBRX $1.83
- FCPT $23.64
- 52 Week High
- IBRX $6.82
- FCPT $30.12
- Technical
- Relative Strength Index (RSI)
- IBRX 54.54
- FCPT 34.44
- Support Level
- IBRX $2.30
- FCPT $24.44
- Resistance Level
- IBRX $2.67
- FCPT $24.80
- Average True Range (ATR)
- IBRX 0.12
- FCPT 0.32
- MACD
- IBRX 0.01
- FCPT 0.04
- Stochastic Oscillator
- IBRX 75.68
- FCPT 14.61
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About FCPT Four Corners Property Trust Inc.
Four Corners Property Trust Inc is a real estate investment trust predominantly engaged in the ownership, acquisition and leasing of restaurant and retail properties. The company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries. The firm operates through two segments namely, real estate operations and restaurant operations. The real estate operations segment consists of rental revenues generated by leasing restaurant and retail properties to tenants. The restaurant operations segment is conducted through a taxable REIT subsidiary (TRS) and consists of Kerrow Restaurant Operating Business. The firm generates majority of the revenue from the real estate operations segment.